LT3139925T - Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus - Google Patents

Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus

Info

Publication number
LT3139925T
LT3139925T LTEPPCT/US2015/029519T LT15029519T LT3139925T LT 3139925 T LT3139925 T LT 3139925T LT 15029519 T LT15029519 T LT 15029519T LT 3139925 T LT3139925 T LT 3139925T
Authority
LT
Lithuania
Prior art keywords
valbenazine
treatment
movement disorders
dosage regime
hyperkinetic movement
Prior art date
Application number
LTEPPCT/US2015/029519T
Other languages
English (en)
Inventor
Christopher O'brien
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of LT3139925T publication Critical patent/LT3139925T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LTEPPCT/US2015/029519T 2014-05-06 2015-05-06 Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus LT3139925T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
LT3139925T true LT3139925T (lt) 2022-01-25

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP21178882.3T LT3936130T (lt) 2014-05-06 2015-05-06 Valbenazino dozavimo schema, skirta hiperkinetinio judrumo sutrikimų gydymui
LTEPPCT/US2015/029519T LT3139925T (lt) 2014-05-06 2015-05-06 Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP21178882.3T LT3936130T (lt) 2014-05-06 2015-05-06 Valbenazino dozavimo schema, skirta hiperkinetinio judrumo sutrikimų gydymui

Country Status (24)

Country Link
US (3) US20170071932A1 (lt)
EP (3) EP3936130B1 (lt)
JP (4) JP6635945B2 (lt)
KR (5) KR20240011255A (lt)
CN (3) CN112741836A (lt)
AU (1) AU2015256012B2 (lt)
CA (1) CA2947736C (lt)
CY (1) CY1125058T1 (lt)
DK (2) DK3139925T3 (lt)
ES (2) ES2976207T3 (lt)
FI (1) FI3936130T3 (lt)
HR (2) HRP20240459T1 (lt)
HU (2) HUE057839T2 (lt)
IL (1) IL248745B (lt)
LT (2) LT3936130T (lt)
MX (1) MX387625B (lt)
NZ (1) NZ725826A (lt)
PL (2) PL3139925T3 (lt)
PT (2) PT3139925T (lt)
RS (2) RS65359B1 (lt)
RU (1) RU2753740C2 (lt)
SI (2) SI3936130T1 (lt)
SM (2) SMT202400199T1 (lt)
WO (1) WO2015171802A1 (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284874B2 (en) * 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2768738C2 (ru) * 2017-04-01 2022-03-24 Адептио Фармасьютикалз Лимитед ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020003421A (es) * 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
EP3733666B1 (en) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MX2021013132A (es) * 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2938581C (en) * 2014-02-07 2023-02-28 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
KR20200133003A (ko) 2020-11-25
KR20220140647A (ko) 2022-10-18
EP3936130B1 (en) 2024-02-14
US20170071932A1 (en) 2017-03-16
WO2015171802A1 (en) 2015-11-12
JP2019218407A (ja) 2019-12-26
JP2021191799A (ja) 2021-12-16
JP2024153782A (ja) 2024-10-29
CN112741836A (zh) 2021-05-04
KR20160147044A (ko) 2016-12-21
ES2976207T3 (es) 2024-07-26
RS62782B1 (sr) 2022-01-31
SI3139925T1 (sl) 2022-04-29
LT3936130T (lt) 2024-04-25
HUE066361T2 (hu) 2024-07-28
EP4389227A3 (en) 2024-09-04
HRP20220025T1 (hr) 2022-04-01
PL3936130T3 (pl) 2024-06-10
CN106456629A (zh) 2017-02-22
AU2015256012A1 (en) 2016-11-24
PT3139925T (pt) 2022-01-26
US20200101063A1 (en) 2020-04-02
CN112741835A (zh) 2021-05-04
PT3936130T (pt) 2024-04-17
AU2015256012B2 (en) 2020-07-23
SMT202400199T1 (it) 2024-07-09
DK3139925T3 (da) 2021-12-20
EP3936130A1 (en) 2022-01-12
DK3936130T3 (da) 2024-03-25
MX387625B (es) 2025-03-18
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
IL248745A0 (en) 2017-01-31
CY1125058T1 (el) 2023-06-09
JP6635945B2 (ja) 2020-01-29
US20210196702A1 (en) 2021-07-01
KR20250029267A (ko) 2025-03-04
ES2904526T3 (es) 2022-04-05
HUE057839T2 (hu) 2022-06-28
SMT202200193T1 (it) 2022-07-21
IL248745B (en) 2022-07-01
CA2947736A1 (en) 2015-11-12
RU2016147523A3 (lt) 2018-12-28
JP2017514850A (ja) 2017-06-08
EP3139925B1 (en) 2021-12-01
MX2016014429A (es) 2017-04-06
NZ725826A (en) 2023-05-26
CA2947736C (en) 2023-04-18
EP4389227A2 (en) 2024-06-26
PL3139925T3 (pl) 2022-03-21
SI3936130T1 (sl) 2024-05-31
KR20240011255A (ko) 2024-01-25
RU2016147523A (ru) 2018-06-08
RU2753740C2 (ru) 2021-08-23

Similar Documents

Publication Publication Date Title
PT3936130T (pt) Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos
IL250016B (en) Antisense oligonucleotides for the treatment of usher syndrome type 2
IL247452A0 (en) Compounds for treatment of complement mediated disorders
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
PL3107900T3 (pl) Pochodne 5-benzyloizochinoliny do leczenia chorób sercowo-naczyniowych
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
LT3244889T (lt) Farmacinė kompozicija, skirta mikozės gydymui
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
PL3119752T3 (pl) Związki 3,4-diamino-6-chloropirazyno-2-karbokysamidowe do leczenia chorób mediowanych przez ENAC
DK3270923T3 (da) Terapeutisk middel til frontallapsdysfunktion
PT3139932T (pt) Regime de tratamento para composto de tiacumicina
ITUB20155450A1 (it) Composizione per il trattamento delle dermatiti.
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
ITUB20156862A1 (it) Composizioni per il trattamento della psoriasi.
ES1113580Y (es) Dispositivo dental para el tratamiento de la onicofagia